Discovery Laboratories, Inc. (DSCO) Misses Q1 EPS by 1c

Discovery Laboratories, Inc. (NASDAQ: DSCO) reported Q1 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13).

"The first quarter of 2014 was important as we began to position our products and programs to transform the management of neonates with respiratory distress syndrome, or RDS," commented John G. Cooper, President and Chief Executive Officer at Discovery Labs. "We completed our first full quarter of the SURFAXIN launch, and consistent with our measured approach, we are communicating to hospitals the attributes of a scientifically engineered, synthetic KL4 surfactant product - the only approved alternative to the animal-derived surfactants that have been used for the past decade to manage RDS. We also expect to announce the first clinical data in the third quarter of 2014 from our ongoing phase 2a clinical trial for AEROSURF, a product opportunity that could generate a significant paradigm shift in the management of infants at risk for RDS. As we introduce our RDS portfolio based on our synthetic KL4 technology, we are developing important relationships in key centers of influence across the U.S. as part of our efforts to improve the standard of care for infants born at risk of this condition."

For earnings history and earnings-related data on Discovery Laboratories, Inc. (DSCO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• Vivos Therapeutics posts 35% revenue gain but widens net loss